Identifying pathogenic CFTR variants in patients with pancreatitis clarifies etiology, enables timely diagnosis, and guides management—potentially including CFTR modulators (e.g., ivacaftor), which are currently only approved for patients with formal diagnoses of CF. Here, CFTR is linked to cystic fibrosis.